The pharma terms, defined.

The FDA regulation setting requirements for electronic records and electronic signatures to be trustworthy and equivalent to paper — audit trails, access controls and validated systems.

A preset monitoring threshold that, when exceeded, obliges a defined, documented response — not merely a review.

The data-integrity principles regulators expect records to meet: Attributable, Legible, Contemporaneous, Original and Accurate — plus Complete, Consistent, Enduring and Available.

A preset monitoring threshold that, when exceeded, signals a drift from normal and triggers review before control is lost.

The EU GMP annex governing manufacture of sterile medicinal products. The 2022 revision put the contamination control strategy at its centre and raised the bar on demonstrated, not just documented, control.

Manufacturing that maintains sterility by excluding contamination at every step, used when a product cannot be terminally sterilised in its final container.

The complete documented history of a production batch, showing that it was made and controlled according to the approved process.

The population of viable microorganisms present on a raw material, component or product prior to sterilisation.

A medicinal product manufactured in or derived from living systems — such as vaccines, monoclonal antibodies and cell or gene therapies.

The systematic process of investigating a problem, correcting it, and preventing recurrence — a backbone of any quality management system.

The EU GMP cleanliness classes for controlled environments. Grade A is the critical zone where sterile product is exposed; Grade B is its background; C and D are for less critical stages.

A risk-based FDA approach to validating computerised systems that favours critical thinking and targeted testing over exhaustive documentation.

A documented, site-wide set of controls for microbial, particulate and pyrogen contamination, with a rationale linking each identified risk to a control and its monitoring.

Producing drug product in an uninterrupted flow rather than discrete batches, enabling tighter control, smaller footprints and faster release.

A Contract Development and Manufacturing Organisation that develops and/or produces product on behalf of another company.

The assurance that data is complete, consistent and accurate throughout its lifecycle — the foundation of trustworthy GMP records and regulatory decisions.

A departure from an approved instruction, procedure or specification, requiring documented investigation and disposition.

Routine sampling of cleanroom air, surfaces and personnel for microbial and particulate contamination, used to demonstrate a controlled state over time.

A monitoring result that breaches an alert or action limit, requiring investigation and, at the action limit, a defined response.

Chemicals that can migrate from contact materials (such as single-use assemblies) into product — assessed to confirm patient safety.

The form an FDA investigator issues at the close of an inspection, listing observed conditions that may violate GMP requirements.

The system of regulations, procedures and controls ensuring that medicinal products are consistently produced and controlled to quality standards appropriate to their use.

A sealed, decontaminated enclosure that provides a controlled Grade A environment for aseptic work, fully separating the operator from the process.

Software that manages samples, tests, results and associated data across a laboratory, supporting traceability and data integrity.

Removing water from a frozen product under vacuum to yield a stable dry cake — common for biologics and reconstitutable injectables.

A process simulation that runs sterile growth media through the line in place of product, used to validate that aseptic processing keeps the product sterile.

Software that manages and records production on the shop floor in real time, enforcing the process and replacing paper batch records.

A class of probable carcinogenic impurities that can form in some drug substances and products, prompting risk assessments and control limits.

Documented evidence that a process, operated within set parameters, consistently produces product meeting its predetermined quality attributes.

A systematic development approach that builds quality into a product by understanding and controlling the process, rather than testing quality in at the end.

Technologies that return microbial results faster than traditional plate counts, shortening the loop between detection and action and enabling quicker release.

A physical and aerodynamic barrier that limits operator contact with the critical (Grade A) zone during aseptic processing.

Disposable, pre-sterilised components — bags, tubing and assemblies — used once and discarded, reducing cleaning and cross-contamination risk.

The overall confidence — built from design, process control and monitoring — that a product is sterile, rather than sterility inferred from an end-product test alone.